• BG Medicine Inc., of Waltham, Mass., said results of a research study conducted at the Massachusetts General Hospital provided additional evidence that elevated levels of galectin-3 predict adverse outcomes in chronic heart failure and suggested the prognostic value of the noninvasive biomarker may be enhanced when serial measurements are made over time.
Suite: 1100 | Atlanta, Georgia 30346, USA
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter